Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (989)

Search Parameters:
Keywords = CXCR6

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
12 pages, 377 KB  
Article
Immune-Related Gene Variants as Modifiers of Multiple Sclerosis Severity
by Olga Kulakova, Natalia Baulina, Maxim Kozin, Natalia Matveeva, Alexey Boyko, Olga Favorova and Ivan Kiselev
Int. J. Mol. Sci. 2026, 27(12), 5347; https://doi.org/10.3390/ijms27125347 (registering DOI) - 13 Jun 2026
Abstract
Multiple sclerosis (MS) is a heterogeneous autoimmune disorder of the central nervous system of polygenic nature. Uncovering the genetic predictors of MS phenotype can help to explain the nature of the disease’s clinical heterogeneity, and contribute to the development of novel tools for [...] Read more.
Multiple sclerosis (MS) is a heterogeneous autoimmune disorder of the central nervous system of polygenic nature. Uncovering the genetic predictors of MS phenotype can help to explain the nature of the disease’s clinical heterogeneity, and contribute to the development of novel tools for precise disease prognosis. We conducted a retrospective genetic association study of 35 polymorphic variants in immune-related genes with MS severity assessed using the Multiple Sclerosis Severity Score (MSSS) in a sample of 548 Russian relapsing-onset MS patients who have not previously received immunomodulatory therapy. Variants in the CXCR5, EOMES, TNFRSF1A, IRF8, PVT1, CCR5, HLA-DRB1, IL6, TCF7, and CD40 genes were identified as MSSS-associated in at least two of the three models analyzed (MSSS > 3.5 versus ≤3.5; MSSS > 5.0 versus <2.5; MSSS as a continuous variable). Among them, variants in CCR5, HLA-DRB1 and IL6 genes were associated with MSSS only in women, while variants in the TCF7 and CD40 genes only in men. The variant in CXCR5 was MSSS-associated both in the total sample and in subgroups of female and male MS patients. Thus, we demonstrate that several GWAS-identified MS risk genes, along with other immunological loci, act as modifiers of the MS phenotype. Full article
20 pages, 1928 KB  
Article
CD40LG/CD28-Mediated Rho GTPase Signaling Drives Survival and Chemoresistance in Non-ETP T-ALL.
by Yan Yang, Wei Lu, Zhexi Zhu, Chenyang Li, Zihao Guo and Han Zhang
Int. J. Mol. Sci. 2026, 27(12), 5306; https://doi.org/10.3390/ijms27125306 - 11 Jun 2026
Viewed by 60
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subtype of ALL characterized by unfavorable clinical outcomes. Despite significant progress in deciphering the genetic and epigenetic landscapes of T-ALL, the underlying molecular mechanisms, particularly in non-early T-cell precursor (non-ETP) T-ALL, remain incompletely understood. In [...] Read more.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subtype of ALL characterized by unfavorable clinical outcomes. Despite significant progress in deciphering the genetic and epigenetic landscapes of T-ALL, the underlying molecular mechanisms, particularly in non-early T-cell precursor (non-ETP) T-ALL, remain incompletely understood. In this study, functional assays were performed using three well-characterized non-ETP T-ALL cell lines. In vivo therapeutic efficacy was evaluated using non-ETP T-ALL xenograft models. Transcriptomic profiling was performed by RNA sequencing (RNA-seq) followed by bioinformatic analysis. Publicly available clinical datasets from T-ALL patients were mined to analyze survival outcomes. We found that activation of CD40 ligand (CD40LG) or CD28 accelerates cell-cycle progression and enhances the migratory capacity of non-ETP T-ALL cells, with CD40LG uniquely upregulating CXCR4 to mediate bone marrow tropism. Further RNA-seq and functional validation identified Rho GTPase signaling, specifically RhoA/Rac1/Rac2, as a pivotal downstream effector of CD40LG/CD28, leading to therapeutic resistance to PI3K inhibition. Pharmacological blocking RhoA or Rac1 using small-molecule compounds not only induces remarkable cytotoxicity but also sensitizes resistant cells to PI3K inhibitors, both in vitro and in vivo. Clinically, elevated expression of CD40LG, CD28, RHOA, or RAC2 correlates with poor prognosis in non-ETP T-ALL patients. These findings uncover a novel CD40LG/CD28-Rho GTPase axis as a key driver of pathogenesis and a potential therapeutic vulnerability in non-ETP T-ALL, providing a new target for precision intervention and a promising strategy to overcome therapeutic resistance. Full article
(This article belongs to the Topic Recent Advances in Anticancer Strategies, 2nd Edition)
28 pages, 970 KB  
Review
The Immune-Chemokine Axis in Alzheimer’s Disease: Roles of Adaptive Immune System in Neuroinflammation and Disease Progression
by José Joaquín Merino, José Julio Rodríguez-Arellano, Xavier Busquets, Isabel Álvarez-Vicente, María Eugenia Cabaña-Muñoz, Ana Isabel Flores and Adolfo Toledano Gasca
Biomolecules 2026, 16(6), 855; https://doi.org/10.3390/biom16060855 - 11 Jun 2026
Viewed by 224
Abstract
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β (Aβ) and the accumulation of tau in the brain, which triggers robust innate immune responses. Growing evidence indicates that neuroinflammation contributes to AD progression by overactivating microglia through the release of cytokines [...] Read more.
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β (Aβ) and the accumulation of tau in the brain, which triggers robust innate immune responses. Growing evidence indicates that neuroinflammation contributes to AD progression by overactivating microglia through the release of cytokines and chemokines. In general, chemokines can disrupt neuronal communication and promote blood–brain barrier permeability. Peripheral immune cells are mobilized into the brain by a gradient of chemokines. These processes link peripheral immune responses with substantial T-cell infiltration into the CNS parenchyma, leptomeninges and cerebrospinal fluid of both AD mice and AD patients. This finding underscores the relevance of the adaptive immune system, particularly T and B cells, in AD neuropathology. T-cell infiltration into the brain can influence amyloid clearance through chemokine signalling. However, chemokines play a critical role in AD by either promoting or suppressing disease progression. The infiltration of peripheral T and B cells into the brain parenchyma can exacerbate neuronal loss, yet it may also exert neuroprotective effects. Despite the presence of CD4+ and CD8+ T cells in postmortem brains of AD patients, debate continues about their role in AD brains, in terms of whether they are protective or detrimental. Understanding the complex role of chemokines in controlling innate and adaptive immune responses by modulating neuron–glia interactions (involving astrocytes and microglia) may provide novel therapeutic approaches for AD. Targeting chemokine signalling or treating with drugs that can prevent the recruitment of immune cells may be promising strategies for treating AD neuropathology. Therapies that prevent the overactivation of T cells in the brain could lead to protective strategies against AD. In fact, regulatory T cells (Tregs) could delay the onset of cognitive symptoms, because they suppress inflammation and slow the accumulation of Aβ plaques and p-Tau in the brain. Complementary strategies, such as photobiomodulation, nanoparticle, and T-cell-based approaches, could mitigate AD progression in patients. Full article
Show Figures

Figure 1

18 pages, 677 KB  
Review
Beta-Blocker Utilization in Intracranial Arteriovenous Malformations: A Narrative Review of Current Evidence, Mechanistic Rationale, and Potential Adjunctive Therapeutic Applications
by Thamer Alsharif, Badr Hafiz, Alaa Turkistani, Ziad Alzahrani, Faisal Sukkar, Fahad Okal, Afnan Alkhotani, Mohammed Aref, Mohammed Binmahfoodh and Saleh Baeesa
Brain Sci. 2026, 16(6), 626; https://doi.org/10.3390/brainsci16060626 - 11 Jun 2026
Viewed by 133
Abstract
Background/Objective: Intracranial arteriovenous malformations (AVMs) are high-flow cerebrovascular lesions associated with a significant risk of intracranial hemorrhage, neurological morbidity, and mortality. Current management strategies, including microsurgical resection, endovascular embolization, stereotactic radiosurgery, and conservative observation, remain limited by procedural risk and uncertain long-term outcomes. [...] Read more.
Background/Objective: Intracranial arteriovenous malformations (AVMs) are high-flow cerebrovascular lesions associated with a significant risk of intracranial hemorrhage, neurological morbidity, and mortality. Current management strategies, including microsurgical resection, endovascular embolization, stereotactic radiosurgery, and conservative observation, remain limited by procedural risk and uncertain long-term outcomes. Beta-blockers, particularly propranolol, have recently attracted interest as potential adjunctive therapies because of their vasoconstrictive, antiangiogenic, and vascular remodeling properties. This review evaluates the mechanistic rationale and current evidence regarding beta-blocker use in intracranial AVMs. Methods: A comprehensive literature review was conducted using PubMed, Scopus, and Google Scholar databases through January 2026 using combinations of the terms “arteriovenous malformation,” “AVM,” “beta-blocker,” “propranolol,” “angiogenesis,” “hemorrhage,” and “cerebral cavernous malformation.” Eligible studies included experimental investigations, translational studies, observational cohorts, case reports, clinical trials, systematic reviews, and meta-analyses evaluating beta-blocker use in intracranial AVMs or related vascular malformations. Studies unrelated to cerebrovascular lesions, duplicate reports, and non-English publications were excluded. Given the heterogeneity and limited volume of available AVM-specific literature, findings were synthesized narratively rather than through formal systematic review methodology. Discussion: Preclinical studies suggest that beta-blockers modulate molecular pathways implicated in AVM pathophysiology, including VEGF, HIF-1α, SDF1α/CXCR4, MMP-9, and Notch-associated signaling. These mechanisms may reduce abnormal angiogenesis, endothelial instability, and pathological vascular remodeling. Clinical evidence, however, remains limited to retrospective studies, perioperative reports, and indirect evidence from cerebral cavernous malformations. Observational studies have reported associations between beta-blocker exposure and certain favorable AVM characteristics, including lower rates of hemorrhagic presentation and less complex angioarchitecture. However, these findings are highly susceptible to confounding, reverse causation, and selection bias and should not be interpreted as evidence of disease modification. Conclusions: Beta-blockers cannot currently be recommended as definitive therapy for intracranial AVMs. Their established role remains perioperative hemodynamic control, while potential disease-modifying effects require validation through prospective studies and randomized clinical trials. Full article
(This article belongs to the Special Issue Cerebrovascular Disease: Update on Diagnosis and Treatment)
Show Figures

Figure 1

9 pages, 461 KB  
Proceeding Paper
Genome-Wide Variant Associations and Biological Pathways in Postherpetic Neuralgia
by Carlos Domínguez-Vargas, Jesús Eduardo García-Hernández, Emiliano Peña-Durán, Miranda Citlali Pérez-Castellón, Dante Joel Márquez-González, Diana Margarita Robles-Loera, Paloma Marylí Prado-López, Paola Fernanda Olmos-Suazo, Ramsés Emiliano Martínez-Hernández, Topacio Olivier Andrade-Romo and Gerardo Amaya-Tapia
Med. Sci. Forum 2026, 46(1), 2; https://doi.org/10.3390/msf2026046002 - 9 Jun 2026
Viewed by 78
Abstract
Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition that arises following varicella-zoster virus reactivation and represents a significant clinical burden. Despite known risk factors, the genetic basis of PHN remains poorly understood. This study aimed to identify genetic variants associated with PHN [...] Read more.
Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition that arises following varicella-zoster virus reactivation and represents a significant clinical burden. Despite known risk factors, the genetic basis of PHN remains poorly understood. This study aimed to identify genetic variants associated with PHN through the secondary analysis of GWAS summary data (GCST012124). One genome-wide significant locus (KIF1B) and several suggestive variants (PTPRZ1, PRKCE, CXCR4) were identified. These genes converge on pathways related to axonal transport, neuroinflammation, and nociceptive sensitization. Findings support a multifactorial genetic contribution to PHN and highlight potential targets for future research and therapeutic development. Full article
Show Figures

Figure 1

27 pages, 3648 KB  
Review
Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions
by Tereza Růžičková, Michal Kaščák, Zuzana Chyra, Viera Sandecká, Jana Kotašková and Sabina Ševčíková
Int. J. Mol. Sci. 2026, 27(12), 5173; https://doi.org/10.3390/ijms27125173 - 7 Jun 2026
Viewed by 126
Abstract
Waldenström macroglobulinemia is a rare lymphoplasmacytic malignancy characterized by bone marrow infiltration and monoclonal immunoglobulin M production. Despite its indolent clinical course, the disease exhibits considerable biological complexity driven by recurrent genetic alterations, dysregulated signaling pathways, and a supportive bone marrow microenvironment. The [...] Read more.
Waldenström macroglobulinemia is a rare lymphoplasmacytic malignancy characterized by bone marrow infiltration and monoclonal immunoglobulin M production. Despite its indolent clinical course, the disease exhibits considerable biological complexity driven by recurrent genetic alterations, dysregulated signaling pathways, and a supportive bone marrow microenvironment. The identification of MYD88 and CXCR4 mutations has significantly advanced understanding of disease pathogenesis, clonal evolution, and treatment response. Additional insights from cytogenetic, epigenetic, and microRNA studies have further refined the molecular landscape of this disorder. These advances have translated into improved therapeutic strategies, particularly with the introduction of Bruton’s tyrosine kinase inhibitors, although treatment resistance remains a clinical challenge. Other targeted approaches, including BCL2 and proteasome inhibition, offer additional options for personalized therapy. Ongoing integration of molecular and microenvironmental data is expected to enhance risk stratification and support the development of more effective, tailored treatment strategies. Full article
Show Figures

Figure 1

21 pages, 4911 KB  
Article
A Dual-Gene Signature of PMAIP1 and GADD45A for Early Detection of Intrahepatic Cholangiocarcinoma in the Context of Primary Sclerosing Cholangitis
by Bei Yao, Yiming Ma, Shuang Guan, Qiguang Zheng, Yanan Yu, Ran Jia, Yinli Shi, Zhiyong Hou, Zhong Wang and Jun Liu
Int. J. Mol. Sci. 2026, 27(11), 4826; https://doi.org/10.3390/ijms27114826 - 27 May 2026
Viewed by 156
Abstract
Primary sclerosing cholangitis (PSC) is a chronic inflammatory precursor associated with an increased risk of intrahepatic cholangiocarcinoma (ICC), yet identifying malignant features within the persistent inflammatory background remains challenging. In this study, a background-deviation framework was applied to explore malignant-associated determinants during PSC-associated [...] Read more.
Primary sclerosing cholangitis (PSC) is a chronic inflammatory precursor associated with an increased risk of intrahepatic cholangiocarcinoma (ICC), yet identifying malignant features within the persistent inflammatory background remains challenging. In this study, a background-deviation framework was applied to explore malignant-associated determinants during PSC-associated cholangiocarcinogenesis. Single-cell RNA sequencing data from PSC, ICC tumor tissues, and adjacent non-tumor tissues were integrated, followed by functional enrichment, CellChat analysis, Monocle 2 pseudotime reconstruction, Non-negative Matrix Factorization (NMF), STRING/Cytoscape network analysis, and diagnostic signature construction using LASSO regression and exhaustive best subset selection. Single-cell profiling suggested disease-associated cellular remodeling, including cholangiocyte expansion in ICC samples. Functional and intercellular communication analyses indicated a putative transition from an immune-dominant PSC state toward a hyper-biosynthetic ICC-associated phenotype, accompanied by a possible MIF receptor-usage shift from CXCR4 to CD44. Monocle 2 and NMF further identified candidate malignant-associated trajectories and meta-programs, with MYC/TP63-related regulatory signals emerging as potential contributors. Based on these exploratory findings, best subset selection identified a two-gene transcriptomic candidate signature comprising PMAIP1 and GADD45A, which showed promising discriminative performance in internal cross-validation and an external tumor-versus-adjacent validation cohort. These findings provide a transcriptomic basis for further validation of PSC-associated cholangiocarcinogenesis and potential ICC surveillance markers. Full article
(This article belongs to the Section Molecular Oncology)
Show Figures

Figure 1

20 pages, 6350 KB  
Article
Integrated Single-Cell Transcriptomics Identifies γδ T-Cell Heterogeneity and a Candidate HLA-E–NKG2A Regulatory Axis in Pancreatic Ductal Adenocarcinoma
by Saikat Mandal, Shirin R. Hasan, Arkadeep Dhali and Manideepa Maji
Cancers 2026, 18(11), 1723; https://doi.org/10.3390/cancers18111723 - 25 May 2026
Viewed by 348
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) has a profoundly immunosuppressive tumour microenvironment (TME) that limits anti-tumour immunity and contributes to resistance to immunotherapy. Although γδ T-cells can integrate innate and adaptive immune signals, their abundance, transcriptional states and regulatory pathways in PDAC remain incompletely [...] Read more.
Background: Pancreatic ductal adenocarcinoma (PDAC) has a profoundly immunosuppressive tumour microenvironment (TME) that limits anti-tumour immunity and contributes to resistance to immunotherapy. Although γδ T-cells can integrate innate and adaptive immune signals, their abundance, transcriptional states and regulatory pathways in PDAC remain incompletely defined. Methods: We performed integrated single-cell RNA sequencing analysis of 39 pancreatic tissue samples, comprising 33 PDAC tumours and 6 adjacent normal tissues. After dataset integration, immune cell annotation, and stringent per-cell gating, γδ T-cells were quantified and profiled for checkpoint-, ligand-, and chemokine-related programmes. Results: γδ T-cells were detectable across PDAC samples but showed substantial inter-sample heterogeneity in abundance. Among candidate inhibitory pathways, PDCD1, CD274, and HAVCR2 expression in γδ T-cells did not differ significantly between tumour and adjacent tissues, whereas KLRC1 (encoding NKG2A) showed a tumour-associated difference at the single-cell level, with a consistent directional pattern in sample-level summaries. NKG2A expression was comparable between γδ T-cells and NK cells, suggesting a shared inhibitory programme. HLA-E, the ligand for NKG2A, showed higher epithelial-cell expression in tumour than adjacent tissue in sample-level summaries (median 1.06 vs. 0.57; BH-q = 0.035). Chemokine analysis identified enrichment of CCL2, CCL4, CCL5, CXCL8 and CXCL12, with limited CXCL9/10/11 signalling within the PDAC TME. Within γδ T-cells, CXCR4 was the trafficking receptor, followed by CCR6, CCR7 and CXCR6. Conclusions: PDAC-infiltrating γδ T-cells show marked inter-sample heterogeneity and variable inhibitory and trafficking-related programmes. Integrated transcriptomic analysis nominates HLA-E–NKG2A as a candidate regulatory axis, with NK cells included as a biologically relevant comparator. Chemokine receptor patterns, particularly CXCR4, CCR6, CCR7 and CXCR6, suggest candidate trafficking features. These findings are hypothesis-generating and require spatial, protein-level and functional validation. Full article
(This article belongs to the Section Tumor Microenvironment)
Show Figures

Figure 1

21 pages, 11226 KB  
Article
Population Structure Analysis and Candidate Gene Screening for Twinning Trait in Simmental Cattle
by Kailun Ma, Xiaoyun Liang, Lei Xu, Xue Li, Hongkun Zhao, Jiajie Huang, Jingjing Wen, Menghua Zhang, Dan Wang, Xixia Huang and Qiuming Chen
Animals 2026, 16(10), 1567; https://doi.org/10.3390/ani16101567 - 21 May 2026
Viewed by 330
Abstract
Chinese Simmental cattle are a high-quality breed developed through long-term crossbreeding and selection after their introduction into China and have become the main dual-purpose cattle population in the Xinjiang region. To deeply dissect the population structure, characteristics of the population structure, and the [...] Read more.
Chinese Simmental cattle are a high-quality breed developed through long-term crossbreeding and selection after their introduction into China and have become the main dual-purpose cattle population in the Xinjiang region. To deeply dissect the population structure, characteristics of the population structure, and the genetic basis of the twinning trait, this study focused on Xinjiang Chinese Simmental cattle as the main research subject. It integrated genomic data from global public databases to systematically conduct population structure analysis, genetic relationship analysis, and genome-wide selection signature analysis. Population genetic analysis revealed that the IBS matrix and G matrix indicated that some individuals from different geographical origins exhibited distant genetic relationships; the Xinjiang population showed the fastest LD decay, suggesting abundant genetic diversity; the inbreeding coefficient based on Runs of Homozygosity (ROH) across populations ranged from 0.036 to 0.063; principal component analysis and phylogenetic tree showed that some individuals from different geographical origins had certain genetic interconnections; admixture analysis indicated that K = 5 was the optimal model, with each population exhibiting clear genetic differentiation and admixture characteristics. Furthermore, by combining Fst and θπ analysis (comparing the Xinjiang population with other geographical populations), a total of 89 candidate genes associated with the twinning trait in Xinjiang Chinese Simmental cattle were screened, including CYP19A1, HORMAD1, GRB14, CADM2, CXCR4, and others that have been reported to be closely related to oogenesis and reproductive function. In summary, this study explores genome-wide genetic differences among Simmental cattle populations from different regions, deepens our understanding of their population structures, and offers new candidate genes and molecular markers for high-fecundity breeding in Simmental cattle. Full article
(This article belongs to the Section Animal Genetics and Genomics)
Show Figures

Figure 1

16 pages, 1918 KB  
Review
Viral Comorbidities Remodel Host Transcriptome and Redox Signaling in an NADPH Oxidase Isoform-Specific Manner
by Rashmi K. Ambasta and Suman R. Das
Viruses 2026, 18(5), 565; https://doi.org/10.3390/v18050565 - 16 May 2026
Viewed by 526
Abstract
Viral comorbidities elicit complex host responses by activating redox-sensitive signaling pathways, prominently those regulated by NADPH oxidase (Nox) enzymes. Nox are critical components of host defense, generating reactive oxygen species (ROS) that modulate key cellular signaling cascades. Under normal physiological conditions, Nox activity [...] Read more.
Viral comorbidities elicit complex host responses by activating redox-sensitive signaling pathways, prominently those regulated by NADPH oxidase (Nox) enzymes. Nox are critical components of host defense, generating reactive oxygen species (ROS) that modulate key cellular signaling cascades. Under normal physiological conditions, Nox activity is tightly controlled; however, viral infections frequently disrupt this regulation, leading to aberrant upregulation of specific Nox isoforms. Elevated expression of individual Nox enzymes has been observed in infections such as influenza A and hepatitis C virus, while simultaneous activation of multiple Nox isoforms occurs in HIV and SARS-CoV infections. Similar patterns of dual or multi-isoform Nox activation are also reported in complex disease states, including diabetes, thrombosis, and fibrosis. MicroRNAs play a crucial role in this process by selectively regulating Nox isoform expression during viral infection, thereby remodeling the host redox environment. Nox-derived ROS influence multiple downstream signaling pathways, including SMAD, MAPK, CXCR-mediated signaling, and the JNK/ERK axis, promoting inflammation and fibrosis that worsen viral disease outcomes. Additionally, several FDA-approved drugs, investigational agents, and microRNA-based therapeutics show promise in modulating Nox activity. Therefore, this article substantiates how viral infections reprogram host transcriptomic and redox signaling networks, contributing to viral pathogenesis and offering potential therapeutic intervention strategies. Full article
(This article belongs to the Section Human Virology and Viral Diseases)
Show Figures

Figure 1

20 pages, 1378 KB  
Review
Prospects of Chimeric Antigen Receptor T-Cell Therapy in Myelofibrosis: From Immunopathogenesis to Therapeutic Strategies
by Lulu Kong, Chunling Fu, Lianggui Song, Wenxiao Wang, Mengchu Ji, Fei Li, Xiaofeng Shi and Wei Chen
Cancers 2026, 18(9), 1493; https://doi.org/10.3390/cancers18091493 - 6 May 2026
Viewed by 1168
Abstract
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal hematopoietic dysregulation, amplification of chronic inflammation, and progressive remodeling of the bone marrow fibrotic niche, clinically manifesting as bone marrow failure, splenomegaly, and systemic inflammatory symptoms. Although Janus kinase (JAK) inhibitors can alleviate symptom [...] Read more.
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal hematopoietic dysregulation, amplification of chronic inflammation, and progressive remodeling of the bone marrow fibrotic niche, clinically manifesting as bone marrow failure, splenomegaly, and systemic inflammatory symptoms. Although Janus kinase (JAK) inhibitors can alleviate symptom burden and reduce spleen size, they have limited capacity to eradicate malignant clones or reverse fibrosis. Allogeneic hematopoietic stem cell transplantation remains the only potentially curative option; however, its application is constrained by advanced age, comorbidities, unavailable donor, and transplant-related risks. Therefore, the development of disease-modifying therapeutic strategies has become a central focus in MF research. Chimeric antigen receptor T (CAR-T)-cell therapy has demonstrated robust efficacy across various hematologic malignancies. Its application in MF holds the potential not only to selectively eliminate malignant hematopoietic clones but also to modulate the immunosuppressive and profibrotic microenvironment through advanced cellular engineering, thereby enabling a dual therapeutic paradigm involving both clonal control and microenvironmental reprogramming. In this context, potential targets and pathways include CD123, myeloproliferative leukemia protein (MPL), fibroblast activation protein (FAP), the TGF-β signaling axis, the CXCR4–CXCL12 niche-regulatory axis, and molecules associated with myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Future strategies may optimize both efficacy and safety through combinatorial approaches, including integration with JAK inhibitors, development of armored CAR-T constructs, and bridging to hematopoietic stem cell transplantation. Collectively, CAR-T-cell therapy offers a promising avenue for shifting MF management from symptomatic control toward true disease modification. Full article
Show Figures

Figure 1

21 pages, 721 KB  
Review
Systematic Review of Monocyte Transcriptomic Profiles as Diagnostic and Prognostic Biomarkers in Colorectal Cancer
by Alicia Podadera-Herreros, Jesús Pilo, Alejandro Rego-Calvo, María Ortega-Castan, Carolina Muriel-López, Daniel Hinojosa-Nogueira, Isabel Moreno-Indias, María del Mar Amaya-Campos, Julia Alcaide-García, Hatim Boughanem, Libia Alejandra García Flores and Manuel Macías-González
Int. J. Mol. Sci. 2026, 27(9), 4143; https://doi.org/10.3390/ijms27094143 - 6 May 2026
Viewed by 500
Abstract
Colorectal cancer (CRC) remains a major global health burden and a leading cause of cancer-related morbidity and mortality. Current blood-based biomarkers lack sufficient sensitivity and specificity, particularly for early detection. In this context, circulating immune-cell transcriptomic profiling has emerged as a promising minimally [...] Read more.
Colorectal cancer (CRC) remains a major global health burden and a leading cause of cancer-related morbidity and mortality. Current blood-based biomarkers lack sufficient sensitivity and specificity, particularly for early detection. In this context, circulating immune-cell transcriptomic profiling has emerged as a promising minimally invasive approach. This systematic review was conducted following a PROSPERO-registered protocol (CRD42024604757) and PRISMA 2020 guidelines to evaluate the diagnostic and prognostic potential of circulating monocyte-related transcriptomic profiles in CRC. Of 295 records identified, six studies met the inclusion criteria. The available evidence consistently supports the diagnostic value of circulating transcriptomic profiles in distinguishing patients with CRC from healthy individuals and in reflecting tumour-associated immune alterations. Monocyte-related signatures, including CXCR2+ monocytes, were associated with disease stage and metastatic features. Epitranscriptomic modifications, such as m6A and m5C, further reinforced their diagnostic relevance, with some studies reporting higher diagnostic accuracy than classical biomarkers. In contrast, evidence for prognostic value remains limited, heterogeneous, and often indirect, largely due to small sample sizes, methodological variability, and reliance on public datasets. Overall, circulating immune-cell transcriptomic profiles are promising non-invasive biomarkers for CRC detection and characterization, although their prognostic utility remains unclear. Methodological heterogeneity limits clinical applicability, highlighting the need for standardized, CRC-specific studies with cell-type-resolved approaches. Full article
Show Figures

Figure 1

31 pages, 6870 KB  
Review
Decoding the Role of MDSCs in Bone Metastasis: Multicellular Interactions and Clinical Implications
by Samaa Alotab, Mariam Zainab, Labibah Labib Khamies, Rasha Alissa and Khalid Said Mohammad
Pharmaceuticals 2026, 19(5), 723; https://doi.org/10.3390/ph19050723 - 2 May 2026
Viewed by 1031
Abstract
Bone metastasis remains a major cause of morbidity in advanced cancer, driven not only by tumor–bone crosstalk but also by profound immune remodeling within the marrow. Myeloid-derived suppressor cells (MDSCs), including polymorphonuclear (PMN-MDSC) and monocytic (M-MDSC) subsets, are increasingly recognized as central effectors [...] Read more.
Bone metastasis remains a major cause of morbidity in advanced cancer, driven not only by tumor–bone crosstalk but also by profound immune remodeling within the marrow. Myeloid-derived suppressor cells (MDSCs), including polymorphonuclear (PMN-MDSC) and monocytic (M-MDSC) subsets, are increasingly recognized as central effectors of this process, integrating inflammatory signals with metabolic and stromal cues to enforce immune suppression and support skeletal colonization. In this review, we synthesize current evidence that bone metastases transform the bone marrow into an “MDSC amplifier,” where vascular and endosteal niches, CXCL12-rich stromal compartments, hypoxia, and adipocyte-derived lipids collectively promote MDSC recruitment, persistence, and functional maturation. We discuss the dominant suppressive programs deployed by MDSCs in bone (e.g., arginase-1 activity, reactive oxygen/nitrogen species, and checkpoint ligand expression), and how these mechanisms converge to impair cytotoxic T-cell and NK-cell responses while fostering regulatory T-cell dominance. Importantly, because the marrow is a hematopoietic organ, bone lesions can also generate systemic consequences through myeloid spillover, providing a mechanistic basis for reduced responsiveness to immune checkpoint blockade in bone-dominant disease. We then evaluate pharmacologic strategies to target MDSCs in the context of bone metastasis, including approaches that block trafficking (e.g., CCR2/CXCR2 axes), deplete or reprogram suppressive myeloid states (e.g., STAT3-directed strategies, differentiation therapy), and disrupt bone-resorptive feedback loops (e.g., receptor activator of NF-κB ligand (RANKL) inhibition and bisphosphonates), emphasizing rational combinations and sequencing to limit marrow toxicity. Finally, we highlight emerging single-cell and spatial profiling tools that can resolve bone-specific heterogeneity in MDSCs and guide biomarker-driven, mechanism-informed therapeutic development. Full article
(This article belongs to the Special Issue Tumor Immunopharmacology, 2nd Edition)
Show Figures

Graphical abstract

20 pages, 2861 KB  
Article
Route-Dependent Mucosal and Systemic Immune Remodeling Induced by a Regulated-Lysis Edwardsiella piscicida Vaccine in Channel Catfish
by Kavi R. Miryala, Roy Curtiss, Vinicius Lima and Banikalyan Swain
Vaccines 2026, 14(5), 410; https://doi.org/10.3390/vaccines14050410 - 1 May 2026
Viewed by 623
Abstract
Background: Edwardsiella piscicida is a significant intracellular pathogen of channel catfish (Ictalurus punctatus) and a major threat to U.S. aquaculture. A recently developed recombinant attenuated vaccine strain (χ16016) uses arabinose-regulated murA expression to trigger delayed cell wall lysis in vivo, [...] Read more.
Background: Edwardsiella piscicida is a significant intracellular pathogen of channel catfish (Ictalurus punctatus) and a major threat to U.S. aquaculture. A recently developed recombinant attenuated vaccine strain (χ16016) uses arabinose-regulated murA expression to trigger delayed cell wall lysis in vivo, ensuring biological containment while conferring strong protection against virulent challenge. Although its efficacy has been demonstrated, the host immune programs underlying protection remain incompletely defined. Methods: We used RNA sequencing to characterize tissue-specific transcriptomic responses in the intestines and kidneys of channel catfish at 7 days post-vaccination. Fish were vaccinated with χ16016 by either bath immersion or intracoelomic (IC) injection, and differentially expressed genes and enriched immune pathways were analyzed to determine how the vaccine delivery route shapes systemic and mucosal immune responses. Results: Across comparisons, 19,101 differentially expressed genes revealed pronounced route- and tissue-dependent immune remodeling. As aquaculture vaccination strategies increasingly prioritize scalability and practical deployment, understanding how the delivery route shapes immune outcomes is critical. Here, IC vaccination induced broader systemic transcriptional changes, particularly in the intestine, whereas bath immunization elicited a more focused yet coordinated mucosal response. Overall, intestinal tissue exhibited greater transcriptional responsiveness than kidney tissue, underscoring its central role in early vaccine-induced immunity. Functional enrichment analyses identified the activation of innate recognition pathways, MAPK and calcium signaling cascades, complement components, antigen processing machinery, and cell adhesion networks. Notably, bath immunization enriched the intestinal immune network for IgA production pathway, which represents an orthology-based mapping of conserved mucosal immune components, alongside the upregulation of IL-6, CXCL12–CXCR4, integrins (α4β7), MHC class II, complement C3, and polymeric immunoglobulin receptor (pIgR). Given that catfish rely primarily on IgM in mucosal immunity, these findings indicate the induction of IgM-mediated mucosal defense rather than classical mammalian IgA responses. Concurrent complement and scavenger receptor signatures suggest a transition toward efficient opsonophagocytic clearance with controlled inflammation at this subacute stage. Conclusions: This study provides the first systems-level view of host transcriptomic responses to a regulated-lysis E. piscicida vaccine in channel catfish. The findings demonstrate that immersion vaccination, although transcriptionally less expansive than injection, effectively activates coordinated mucosal innate and adaptive immune programs, supporting its practical use as a scalable vaccination strategy for aquaculture. Full article
(This article belongs to the Section Veterinary Vaccines)
Show Figures

Figure 1

27 pages, 1698 KB  
Systematic Review
Diagnostic and Prognostic Significance of Chemokines in Head and Neck Cancers: A Systematic Review and Meta-Analysis
by Raneem Alsheikh, Deemah Assami, Dima Nasrallah, Ahmed Arabi, Ahmad Hamdan, Mohamed Ragab Elhadary, Ibrahim Elmakaty and Mohammed Imad Malki
Cancers 2026, 18(9), 1437; https://doi.org/10.3390/cancers18091437 - 30 Apr 2026
Viewed by 580
Abstract
Background: Head and neck cancers (HNCs) represent a global health burden, with high morbidity and mortality largely driven by late-stage diagnosis and heterogeneous clinical outcomes. Reliable biomarkers are needed to improve early detection, prognostic stratification, and therapeutic decision-making. This study evaluates the diagnostic [...] Read more.
Background: Head and neck cancers (HNCs) represent a global health burden, with high morbidity and mortality largely driven by late-stage diagnosis and heterogeneous clinical outcomes. Reliable biomarkers are needed to improve early detection, prognostic stratification, and therapeutic decision-making. This study evaluates the diagnostic and prognostic value of chemokines in HNCs and identifies candidates with clinical relevance. Methods: A comprehensive literature search was conducted on 28 March 2026 across PubMed, Embase, Scopus, Web of Science, and EBSCO. Observational studies involving patients or biological samples with confirmed HNCs were included if they evaluated chemokines as diagnostic or prognostic biomarkers. Risk of bias was assessed using the Newcastle–Ottawa Scale (NOS) for prognostic studies and the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool for diagnostic studies. Meta-analyses were performed for chemokines evaluated in ≥3 studies using the inverse-variance heterogeneity model. Results: Forty-four studies encompassing 7294 participants were included. Prognostic findings were heterogeneous across biomarkers. MIP-3α demonstrated consistently significant associations with poorer survival outcomes. In contrast, IL-8, CXCL10, and CXCR4 showed inconsistent or predominantly non-significant associations with overall survival (OS), disease-free survival (DFS), and locoregional control (LRC). For diagnostic performance, IL-8, in saliva, demonstrated relatively high sensitivity and specificity for oral squamous cell carcinoma. Chemerin showed high diagnostic accuracy, although evidence remains limited. Conclusions: Certain chemokines show potential as diagnostic and prognostic biomarkers in HNCs. However, heterogeneity across tumor types, samples, and methodologies limits evidence. Larger, well-designed studies are needed to validate their clinical utility in risk stratification and personalized management of HNCs. Full article
Show Figures

Graphical abstract

Back to TopTop